drugset / Trial / NCT02329730

Phase IIa Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10

NCT02329730

RandomizedParallel-groupOpen-labelDiagnostic

Summary

Choose healthy subjects and patients with TB, distribute them into different dose groups according to the recombinant EC allergen dose from low to high average. Conducting clinical trials of TB-PPD or placebo as controlled arms intradermal injection. Do specific interferon gamma detection before the skin test,after the test 72h±2h and 144h±2h. Evaluate the safety of the recombinant EC allergy , and provide the appropriate dose range for phase IIb clinical trials.

Timeline

Start
2014-02
Primary completion
2014-06
Completion
2014-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject ESAT6-CFP10 Protein / enzyme biologic 1 ug/ml Intrathecal
Subject ESAT6-CFP10 Protein / enzyme biologic 5 ug/ml Intrathecal
Subject ESAT6-CFP10 Protein / enzyme biologic 10 ug/ml Intrathecal
Subject ESAT6-CFP10 Protein / enzyme biologic 20 ug/ml Intrathecal
Subject tuberculin Diagnostic / imaging agent 0.1 ml Intrathecal

Indications